| Title |
Therapeutic Potential of Baicalein in Alzheimer’s Disease and Parkinson’s Disease
|
|---|---|
| Published in |
CNS Drugs, June 2017
|
| DOI | 10.1007/s40263-017-0451-y |
| Pubmed ID | |
| Authors |
Yanwei Li, Jinying Zhao, Christian Hölscher |
| Abstract |
Alzheimer's disease and Parkinson's disease are the two most common, progressive central neurodegenerative diseases affecting the population over the age of 60 years. Apart from treatments that temporarily improve symptoms, there is no medicine currently available to inhibit or reverse the progression of Alzheimer's disease and Parkinson's disease. In traditional Chinese medicine, the root of Scutellaria baicalensis Georgi is a classic compatible component in the decoction of herbal medicine used for treating central nervous system diseases. Modern pharmacokinetic studies have confirmed that baicalein (5,6,7-trihydroxyflavone) is a major bioactive flavone constituent root of S. baicalensis Georgi. Studies showed that baicalein possesses a range of key pharmacological properties, such as reducing oxidative stress, anti-inflammatory properties, inhibiting aggregation of disease-specific amyloid proteins, inhibiting excitotoxicity, stimulating neurogenesis and differentiation action, and anti-apoptosis effects. Based on these properties, baicalein shows therapeutic potential for Alzheimer's disease and Parkinson's disease. In this review, we summarize the pharmacological protective actions of baicalein that make it suitable for the treatment of Alzheimer's disease and Parkinson's disease, and discuss the potential mechanisms underlying the effects. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Czechia | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 78 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 78 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 14 | 18% |
| Student > Ph. D. Student | 12 | 15% |
| Student > Bachelor | 7 | 9% |
| Researcher | 7 | 9% |
| Lecturer | 5 | 6% |
| Other | 10 | 13% |
| Unknown | 23 | 29% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 14 | 18% |
| Pharmacology, Toxicology and Pharmaceutical Science | 8 | 10% |
| Agricultural and Biological Sciences | 8 | 10% |
| Neuroscience | 6 | 8% |
| Psychology | 4 | 5% |
| Other | 9 | 12% |
| Unknown | 29 | 37% |
Attention Score in Context
This research output has an Altmetric Attention Score of 14. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 27 December 2023.
All research outputs
#2,563,566
of 25,064,526 outputs
Outputs from CNS Drugs
#209
of 1,385 outputs
Outputs of similar age
#46,906
of 322,609 outputs
Outputs of similar age from CNS Drugs
#4
of 20 outputs
Altmetric has tracked 25,064,526 research outputs across all sources so far. Compared to these this one has done well and is in the 89th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,385 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 11.4. This one has done well, scoring higher than 84% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 322,609 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 85% of its contemporaries.
We're also able to compare this research output to 20 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 85% of its contemporaries.